
    
      We examine the efficacy of Venlafaxine-HCL augmentation with the neuroleptic Quetiapine in
      treatment resistant depression in a double-blind randomized clinical trial. Secondary
      objective is the evaluation of pharmacogenetic factors contributing to drug efficacy in
      treatment resistant depression.
    
  